Ki-67在T1期乳腺癌中的表达及其与Her-2和ER的关系

Ki-67 expression in T1 primary breast cancer tissue and its rela- tionship with Her- 2 and ER

目的研究Kj-67在T1期乳腺癌的表达情况，以及其与雌激素受体（ER）、人表皮生长因子受体．2（Her．2）的关系，指导早期乳腺癌的预后判断。方法选择2008年1月至2011年6月的女性新发T1期乳腺癌组织共60例，免疫组化检测Ki-67的表达情况，并分析其表达与临床病理特征和Her-2、ER表达的关系。结果60例T1期乳腺癌中Ki-67阳性表达率为55．0％，Ki-67表达与T1期乳腺癌的病理类型、患者绝经与否无关（P〉0．05）。T1期乳腺癌中，Ki-67的表达在有淋巴结转移组高于无淋巴结转移组（P=0．047，P〈0．05），Ki-67在Her-2阳性组表达高于阴性组（P=0．021，P〈0．05），Ki-67在ER阳性组表达低于ER阴性组（P=0．037，P〈0．05）。结论T1乳腺癌中Ki-67阳性表达者淋巴结转移可能性较大，与Her-2阳性、ER阴性表达正相关，提示预后不良。

Objective To study the expression of Ki-67 in T1 primary breast cancer tissue and its relationship with Her-2 and ER,evaluate the prognosis of early breast cancer. Methods Sixty cases of women T1 primary breast cancer tissues of 60 female cases from January 2008 to June 2011 were selected. The expressions of Ki-67 were detected by immunohistoehemieal method and the relationships between Ki-67 and clinical-pathological features,Her-2 and ER were analysed. Results The expression of Ki-67 in T1 primary breast cancer was 55% among the 60 patients. The expression of Ki-67 was not related with the clinical-pathological type of breast cancer and menopause （P 〉0.05 ）. The expression of Ki-67 in group with lymph node metastasis was higer than in group without lymph node metastasis（P = 0. 047, P 〈 0.05 ）. The expression of Ki-67 in Her-2 positive group was higher than Her-2 negative group （P = 0. 021 ,P 〈 0.05 ）, and the expression of Ki-67 in ER positive group was lower than that of ER negative group （ P = 0.037, P 〈 0.05）. Conclusions The expression of Ki-67 in T1 primary breast cancer indicates the possibility of lymph node metastasis, and its positive correlation with Her-2 positive expression, ER negative expression indicates poor prognosis.